BIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)BIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)BIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)

BIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)

No trades
See on Supercharts

Key stats

Market capitalization
‪31.67 B‬USD
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income (FY)
Revenue (FY)
Shares float
Beta (1Y)
0.52

About Biogen Inc.

CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
ISIN
ARBCOM4601A8
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BIIBD is featured.